TreatmentTrends: Diabetic Retinopathy/Diabetic Macular Edema 2015 (US) is the fourth annual syndicated report series that offers a snapshot of DR and DME market dynamics and the competitive landscape through comprehensive primary research with retinal specialists and general ophthalmologists. The report provides valuable insight into the current and anticipated treatment of patients with DR (including nonproliferative DR [NPDR] and proliferative DR [PDR]) and DME (including focal and diffuse), with a particular focus on the use of intravitreal pharmacotherapies, specifically anti-VEGF agents and long-acting corticosteroid implants. We also assess surveyed physicians’ perceptions of these products for DME—e.g., their advantages and disadvantages, ideal patient types, barriers to growth—and current detailing and messaging efforts for approved DME brands. Respondents are queried about their awareness of and interest in products in development or recently approved for DR or DME.
Questions Answered in This Report:
- While there are no approved therapies for the treatment of DR exclusive of DME, multiple pharmacotherapies are available for the treatment of DME (with some off-label use of these agents for DR). How are patients with different subtypes of DR (NPDR, PDR) and DME (focal and diffuse) currently being managed and treated? How has the treatment algorithm changed compared with the previous three years? Is treatment anticipated to change over the next six months? What factors are driving these anticipated changes?
- Eylea and Ozurdex gained expanded labeling in 2014 to include DME, while Iluvien was approved for DME in 2014 as its first indication. How have these therapies been incorporated into the DME treatment algorithm? How has their availability impacted use of Lucentis 0.3 mg, the first therapy approved for DME, and off-label Avastin? How do physicians perceive each of these agents to perform across multiple product attributes? Has expanded labeling for Eylea and Ozurdex impacted perceptions about these agents, as well as Avastin and Lucentis 0.3 mg, compared with previous years?
- Eylea and Lucentis recently gained expanded labeling to treat DR in patients with DME. How receptive are physicians to prescribing these therapies for patients with DR exclusive of DME with different severity levels of disease? What do physicians perceive as the biggest obstacles to prescribing these agents more for DR? Is treatment of DR expected to change two years from now?
- Multiple therapies are in mid- to late-stage development for the treatment of DME, including Optina, Luminate (ALG-1001), abicipar pegol, AKB-9778, and PF-04634817. How familiar are physicians with these products? How unique do physicians perceive these products to be compared with current therapies, and what are their biggest advantages and disadvantages? Where do physicians expect Optina, the only later-stage emerging therapy, to fit in the DME treatment algorithm?
Markets covered: United States.
Primary research: 99 retinal specialists and general ophthalmologists.
Indication coverage: diabetic retinopathy; diabetic macular edema.
Emerging therapies: Phase II: 4 drugs; preregistration: 1 drug.